Replimune Group Inc
NASDAQ:REPL
Replimune Group Inc
NASDAQ:REPL
Price:
5.94 USD
-7.76%
Market Closed
Updated:
May 21, 2024
Replimune Group Inc
Research & Development
|
Replimune Group Inc
Research & Development Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Replimune Group Inc
NASDAQ:REPL
|
Research & Development
-$168m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$7.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.5B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$4.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-17%
|
See Also
What is Replimune Group Inc's Research & Development?
Research & Development
-168m
USD
-168m
USD
Based on the financial report for Dec 31, 2023, Replimune Group Inc's Research & Development amounts to -168m USD.
What is Replimune Group Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-51%
-51%
Over the last year, the Research & Development growth was -55%. The average annual Research & Development growth rates for Replimune Group Inc have been -50% over the past three years , -51% over the past five years .
You don't have any saved screeners yet
